Cosmetics working group
This article was originally published in The Rose Sheet
Executive Summary
FDA convenes internal working group to investigate cosmetics thought to be on the periphery of OTC drugs, such as those that have an effect on the structure and function of the body, the agency said. "We need to develop a little bit more conversation in terms of what we'd like to see in the marketplace, how we get there, what is appropriate for the consumer to see and that sort of thing," OTC Drugs Division Acting Director Debra Bowen, MD, recently announced. The working group is still in the "formative" stage; members now identifying the project agenda. FDA said it will invite public discussion on the group's findings. The move is one step in FDA's commitment to create a better link between the cosmetics program and the Center for Drug Evaluation & Research, as announced by the agency earlier this year ("The Rose Sheet" April 6, p. 1)
You may also be interested in...
FDA Cosmetics Definition Hampering Harmonization Efforts - L'Oreal Exec
FDA cosmetics regulations are "primitive" and out of date, thus hindering international harmonization of a cosmetics definition, L'Oreal R&D Director Claude Bouillon maintained at the Colipa-sponsored Mutual Understanding meeting in St. Julian's, Malta April 11.
OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"
With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program